Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Stock Is Tanking Today

By George Budwell - Mar 9, 2020 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is getting special attention from the moody market today. Here's why.

What happened

Shares of Clovis Oncology (CLVS 5.26%) are under enormous pressure this morning. The biotech's stock was down by 11% as of 11:25 a.m. EDT.

What's behind this latest weakness? Clovis' shares are getting hammered as a result of the ongoing novel coronavirus sell-off, which is crushing most small-cap biotech stocks at the moment. Clovis, in particular, seems to be getting special attention from the moody market today because of its inability to turn a profit or even curtail its hefty quarterly net losses, despite having a high-value ovarian cancer drug (Rubraca) already on the market.

On top of all that, the steep plunge in crude oil prices is only adding to investors' unease. 

A female cancer patient consulting with her doctor.

Image source: Getty Images.

So what

The key risk factor with this company is its rapidly shrinking cash runway. At the end of the fourth quarter of 2019, Clovis' estimated cash runway stood at about 18 months. Now, the biotech might be able to markedly improve its financial outlook if Rubraca can score a regulatory approval as a treatment for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer this coming May.

This second indication, after all, could be a game-changer for the drug from a commercial standpoint. That being said, Clovis is definitely in "prove it" mode with investors. The company has repeatedly failed to meet expectations on a number of fronts, and there's no guarantee that it will deliver a win for shareholders even with an expanded label for Rubraca in hand.

Now what

If all the stars align, Clovis' shares might be trading at just 1.2 times next year's sales after today's double-digit drop. That's bargain territory to be sure. Nonetheless, this risky biotech stock is still only suited for investors with a sky-high tolerance for risk and volatility, despite its rather attractive valuation.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.80 (5.26%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.